Accomplished pharmaceutical professional with more than 35 years of experience in the design and development of novel drug delivery systems from initial concept through regulatory approval. Innovator with extensive patent portfolio and publication record on novel formulations, treatments, and delivery technologies for the administration of small molecules, biologics, and combination products. Proven track record in assembling and leading multidisciplinary teams to drive innovation.
Jeff has published more than 100 peer reviewed papers (h-index = 58), has authored several book chapters, and spoken at many national and international meetings. He is a prolific inventor with 70 issued US patents and more than 300 patents worldwide. Jeff’s inventions have resulted in ten approved products and numerous others that made it to the clinic. These include a blood substitute (Oxygent™), an ultrasound contrast agent (Imagent®), a ventilation technique termed partial liquid ventilation (LiquiVent®), a hydrogel to prevent post-operative adhesions (FloGel®), and numerous patents related to engineered particles for inhalation (e.g., the PulmoSphere™ technology) which is utilized in inhaled drug products including TOBI® Podhaler™ (Viatris), Bevespi® Aerosphere (AZ), Breztri® Aerosphere (AZ), Symbicort® Aerosphere (AZ), AIRSUPRA® (AZ) and Ciprofloxacin DPI (Bayer). Patents are also directed to aerosol delivery of antiinfectives utilizing combinations of liposome encapsulated and free drug (e.g., Arikayce®, Insmed).
Jeff has received numerous awards including RDD’s Charles G. Thiel Award and the Alexander Fleming Serendipity Award from the London Business School. He is a Fellow of American Association of Pharmaceutical Scientists (AAPS), and the International Society for Aerosols in Medicine (ISAM), is an Associate Editor for Frontiers in Drug Delivery, and serves on the Editorial Board of the J Aerosol Med Pulm Drug Deliv.
